A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias

Leukemia Research

Volumn 22, Issue 8, 1998, Pages 741-749

  Besa, Emmanuel C ^a   Kunselman, Susan ^c   Nowell, Peter C ^b  

^a Department of Surgical Oncology   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

13 cis retinoic acid; Alpha tocopherol; Myelodysplastic syndrome; Recombinant human erythropoietin

Indexed keywords

ALPHA TOCOPHEROL; HEMOGLOBIN; ISOTRETINOIN; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID;

ACUTE LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD TRANSFUSION; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DRY SKIN; EAR DISEASE; ECCHYMOSIS; EPISTAXIS; ERYTHEMA; FEMALE; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; LEUKEMOGENESIS; LIP DISEASE; MALE; MYELODYSPLASTIC SYNDROME; NAIL DISEASE; ORAL DRUG ADMINISTRATION; PANCYTOPENIA; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; TREATMENT OUTCOME; VITAMIN E;

EID: 0031818813     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00057-5     Document Type: Article

References (29)

1. Koeffler H.P., Heitjan D., Mertelsmann R., Kolitz J.E., Schulman P., Itri L., Gunter P., Besa E.C. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood. 71:1988;703-708.
2. Besa E.C., Abrahm J.L., Bartholomew M.J., Hyzinsky M., Nowell P.C. Treatment with 13-cis retinoic acid of transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol. Am J Med. 89:1990;739.
3. Hoffman S.J., Robinson W.A. Use of differentiation-inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia. Am J Hematol. 28:1988;124.
4. the Leukemia Study Group of the Minister of Health and Welfare, Ohno R., Naoe T., Hirano M., Kobayashi M., Hirai H., Tubaki K., Oh H. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Blood. 81:1993;1152.
5. Kurzrock R., Estey E., Talpaz M. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol. 11:1993;1489.
6. Aul C., Runde V., Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood. 82:1993;2967.
7. Kizaki M., Ueno H., Yamazoe Y.et al. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood. 87:1996;725.
8. Negrin R.S., Haeubner D.H., Nagler A., Kobayashi Y., Sklar J., Donlon T., Vincent M., Greenberg P.L. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 76:1990;36.
9. Vadhan-Raj S., Keating M., LeMaistre A., Hittelman W.N., McCredie K., Trujillo J.M., Broxmeyer H.E., Henney C., Gutterman J.U. Effects of recombinant granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 317:1987;1545.
10. Zeigler Z.R., Jones D., Rosenfeld C.S., Shadduck R.K. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. Stem Cells. 11:1993;49.
11. Bowen D., Culligan D., Jacobs A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol. 77:1991;419.
12. Herrmann F., Oster W., Mertelsmann R. Treatment of patients with anemia of malignancy with recombinant human erythropoietin. Contrib Nephrol. 88:1991;238-245.
13. Bessho M., Jinnai I., Matsuda A., Saito M., Hirashima X.X. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning. 8:1990;445.
14. van Kamp H., Prinsze-Postema T.C., Kluin P.M., den Ottolander G.J., Beverstock G.C., Willemze R., Fibbe W.E. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol. 78:1990;488.
15. Stein R.S., Abels R.I., Krantz S.B. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood. 78:1991;1658.
16. Cazzola M., Ponchio L., Beguin Y., Bergamaschi G., Liberato N.L., Fregoni V., Nalli G., Barosi G., Ascari E. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood. 79:1992;29.
17. Stebler C., Tichelli A., Dazzi H., Gratwhol A., Nissem C., Speck B. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria. Exp Hematol. 18:1990;1204.
18. Musto P., Scalzulli P.R., Carotenuto M. Recombinant erythropoietin for myelodysplastic syndromes. Br J Haematol. 91:1995;256-258.
19. Rose E.H., Abels R.I., Nelson R.A., McCullogh D.M., Lessin L. The use of rHuEPO in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol. 89:1995;831-837.
20. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 89:1995;67-71.
21. Bennett J.M., Catovsky D., Daniel M.-T.et al. Proposed revised criteria for the classification of the myelodysplastic syndromes. Ann Intern Med. 103:1985;626.
22. Kuritz S.J., Landis J.R., Koch G. A general overview of Mantel-Haenszel methods: applications and recent developments. Annu Rev Public Health. 9:1988;123.
23. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457.
24. Negrin R.S., Haeuber D.H., Nagler A.et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor, a Phase I-II trial. Ann Intern Med. 110:1989;976.
25. Negrin R.S., Stein R., Vardiman J., Doherty K., Cornwell J., Krantz S., Greenberg P.L. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood. 82:1993;737.
26. Ganser A., Seipelt G., Verbeek W.et al. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia. 8:1994;369.
27. Clark R.E., Lush C.J., Jacobs A., Smith S.A. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet. 1:1987;763.
28. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079-2088.
29. Estey E., Thall P., Andreef M., Beran M., Kantarjian H., O'Brien S., Escuder S., Robertson L.E., Koller C., Kornblau S., Pierce S., Freireich E.J., Deisseroth A., Keating M. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 12:1994;671.